Shares of Arena Pharmaceuticals (US:arna) jumped 12% to $9.40 on Monday ahead of an expected decision on its new diet-drug lorcaserin by U.S. regulators. The Food and Drug Administration is slated to decide on whether to approve the product by June 27.
